ClinicalTrials.gg
CompletedNCT04646889Updated Aug 5, 2022

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

A Phase 1 interventional study of AR882 Single Dose and AR882 Multiple Dose in Renal Impairment, sponsored by Arthrosi Therapeutics. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
157th of 468
46 · median 32
Started
2021
with 21 others
Phase 1
232 of 553
14 open now
Registered
434th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 157th largest by enrollment of the 468 interventional ones that give a count, is one of 22 that started in 2021, is one of 232 in phase 1, and was the 434th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects:

  • Males and non-pregnant, non-lactating females
  • Body weight no less than 50 kg
  • sUA greater than or equal to 4.0 mg/dL

Renal Impaired Subjects:

  • History of chronic renal impairment (> 6 months)

Exclusion criteria

Exclusion Criteria:

All Subjects:

  • within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
  • History of cardiac abnormalities
  • Active peptic ulcer disease or active liver disease
  • History of kidney stones

Renal Impaired Subjects:

  • Requires dialysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Renal Impairment

    Subjects with various degrees of renal impairment

    Drug: AR882 Single Dose · Drug: AR882 Multiple Dose

  • Experimental
    Normal Renal Function

    Subjects with normal renal function

    Drug: AR882 Single Dose · Drug: AR882 Multiple Dose

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) for plasma following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 6 days

  2. Time to maximum plasma concentration (Tmax) following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 6 days

  3. Maximum plasma concentration (Cmax) following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 6 days

  4. Terminal half-life (t 1/2) following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 6 days

  5. Amount excreted (Ae) into urine following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 6 days

  6. Renal clearance (CLr) following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 6 days

  7. AUC for plasma following multiple doses of AR882 in subjects with renal impairment and normal renal function

    Time frame: 15 days

  8. Tmax following multiple doses of AR882 in subjects with renal impairment and normal renal function

    Time frame: 15 days

  9. Cmax following multiple doses of AR882 in subjects with renal impairment and normal renal function

    Time frame: 15 days

  10. t 1/2 following multiple doses of AR882 in subjects with renal impairment and normal renal function

    Time frame: 15 days

Secondary outcomes

  1. Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following a single dose of AR882 in subjects with renal impairment and normal renal function

    Time frame: 14 days

  2. Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following multiple doses of AR882 in subjects with renal impairment and normal renal function

    Time frame: 21 days

07

Study locations

4 sites
  • Arthrosi Investigative Site
    Orlando, Florida 32809, United States
  • Arthrosi Investigative Site
    Dallas, Texas 75230, United States
  • Arthrosi Investigative Site
    Auckland, New Zealand
  • Arthrosi Investigative Site
    Christchurch, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2022, 17 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Nov 30, 2020
StartActual
Jan 14, 2021
Primary completionActual
Jun 27, 2022
CompletionActual
Jun 27, 2022
Last update
Aug 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04646889
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Nov 30, 2020
Start date
Jan 14, 2021
Primary completion
Jun 27, 2022
Completion
Jun 27, 2022
Last update
Aug 5, 2022

Study contacts

Vijay Hingorani, MD, PhD, MBA
study director · Arthrosi Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AR882

Start the discussion